Regulation of endothelial progenitor cells by prostaglandin E1 via inhibition of apoptosis

Journal of Molecular and Cellular Cardiology

Volumn 42, Issue 3, 2007, Pages 670-677

  Gensch, Christoph ^a   Clever, Yvonne ^a   Werner, Christian ^a   Hanhoun, Milad ^a   Böhm, Michael ^a   Laufs, Ulrich ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Angiogenesis; Apoptosis; Endothelial progenitor cells; Nitric oxide; Prostaglandin

Indexed keywords

ATAXIN 1; HYDROGEN PEROXIDE; ILOPROST; LECTIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E1; STROMAL CELL DERIVED FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 2; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BODY WEIGHT; BONE MARROW; CELL COUNT; CELL FUNCTION; CELL MIGRATION; COMPARATIVE STUDY; CONTROLLED STUDY; EXERCISE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL MOBILIZATION; UPREGULATION;

ALPROSTADIL; ANIMALS; ANTIGENS, LY; APOPTOSIS; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; MALE; MEMBRANE PROTEINS; MICE; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MUS;

EID: 33847677729     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.12.017     Document Type: Article

References (38)

1. Hirsch A.T., Haskal Z.J., Hertzer N.R., Bakal C.W., Creager M.A., Halperin J.L., et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease. Circulation 113 (2006) e463-e654
2. Needleman P., Kulkarni P.S., and Raz A. Coronary tone modulation: formation and actions of prostaglandins, endoperoxides, and thromboxanes. Science 195 (1977) 409-412
3. Sinha A.K., and Colman R.W. Prostaglandin E1 inhibits platelet aggregation by a pathway independent of adenosine 3′,5′-monophosphate. Science 200 (1978) 202-203
4. Marchesi S., Pasqualini L., Lombardini R., Vaudo G., Lupattelli G., Pirro M., et al. Prostaglandin E1 improves endothelial function in critical limb ischemia. J. Cardiovasc. Pharmacol. 41 (2003) 249-253
5. Schror K., and Hohlfeld T. Mechanisms of anti-ischemic action of prostaglandin E1 in peripheral arterial occlusive disease. Vasa 33 (2004) 119-124
6. Mehrabi MR., Serbecic N., Tamaddon F., Kaun C., Huber K., Pacher R., et al. Clinical and experimental evidence of prostaglandin E1-induced angiogenesis in the myocardium of patients with ischemic heart disease. Cardiovasc. Res. 56 (2002) 214-224
7. Kuss M., Heidrich H., and Koettgen E. Hemostatic and fibrinolytic effects of systemic prostaglandin E1 therapy in patients with peripheral arterial disease. Vasa 32 (2003) 145-148
8. Weiss C., Regele S., Velich T., Bartsch P., and Weiss T. Hemostasis and fibrinolysis in patients with intermittent claudication: effects of prostaglandin E1. Prostaglandins Leukot Essent Fatty Acids 63 (2000) 271-277
9. Vaughan D.E., Plavin S.R., Schafer A.I., and Loscalzo J. PGE1 accelerates thrombolysis by tissue plasminogen activator. Blood 73 (1989) 1213-1217
10. Haider D.G., Bucek R.A., Giurgea A.G., Maurer G., Glogar H., Minar E., et al. PGE1 analog alprostadil induces VEGF and eNOS expression in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H2066-H2072
11. Weiss T.W., Mehrabi M.R., Kaun C., Zorn G., Kastl S.P., Speidl W.S., et al. Prostaglandin E1 induces vascular endothelial growth factor-1 in human adult cardiac myocytes but not in human adult cardiac fibroblasts via a cAMP-dependent mechanism. J. Mol. Cell Cardiol. 36 (2004) 539-546
12. Ziche M., Morbidelli L., Masini E., Amerini S., Granger H.J., Maggi C.A., et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J. Clin. Invest. 94 (1994) 2036-2044
13. Asahara T., Murohara T., Sullivan A., Silver M., van der Z.R., Li T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
14. Rafii S., and Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 9 (2003) 702-712
15. Dimmeler S., Aicher A., Vasa M., Mildner-Rihm C., Adler K., Tiemann M., et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest. 108 (2001) 391-397
16. Hill J.M., Zalos G., Halcox J.P., Schenke W.H., Waclawiw M.A., Quyyumi A.A., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348 (2003) 593-600
17. Aicher A., Heeschen C., Mildner-Rihm C., Urbich C., Ihling C., Technau-Ihling K., et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 9 (2003) 1370-1376
18. Werner N., Junk S., Laufs U., Link A., Walenta K., Böhm M., et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ. Res. 93 (2003) e17-e24
19. Shintani S., Murohara T., Ikeda H., Ueno T., Honma T., Katoh A., et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103 (2001) 2776-2779
20. Werner N., Priller J., Laufs U., Endres M., Böhm M., Dirnagl U., et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc. Biol. 22 (2002) 1567-1572
21. Aicher A., Zeiher A.M., and Dimmeler S. Mobilizing endothelial progenitor cells. Hypertension 45 (2005) 321-325
22. Adams V., Lenk K., Linke A., Lenz D., Erbs S., Sandri M., et al. Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia. Arterioscler Thromb Vasc. Biol. 24 (2004) 684-690
23. Laufs U., Werner N., Link A., Endres M., Wassmann S., Jurgens K., et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 109 (2004) 220-226
24. Werner N., Kosiol S., Schiegl T., Ahlers P., Walenta K., Link A., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353 (2005) 999-1007
25. Kojda G., Laursen J.B., Ramasamy S., Kent J.D., Kurz S., Burchfield J., et al. Protein expression, vascular reactivity and soluble guanylate cyclase activity in mice lacking the endothelial cell nitric oxide synthase: contributions of NOS isoforms to blood pressure and heart rate control. Cardiovasc. Res. 42 (1999) 206-213
26. Laufs U., Wassmann S., Czech T., Münzel T., Eisenhauer M., Böhm M., et al. Physical inactivity increases oxidative stress, endothelial dysfunction, and atherosclerosis. Arterioscler Thromb Vasc. Biol. 25 (2005) 809-814
27. Laufs U., Urhausen A., Werner N., Scharhag J., Heitz A., Kissner G., et al. Running exercise of different duration and intensity: effect on endothelial progenitor cells in healthy subjects. Eur. J. Cardiovasc. Prev. Rehabil. 12 (2005) 407-414
28. Heeschen C., Weis M., Aicher A., Dimmeler S., and Cooke J.P. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J. Clin. Invest. 110 (2002) 527-536
29. Urbich C., Knau A., Fichtlscherer S., Walter D.H., Bruhl T., Potente M., et al. FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells. FASEB J. 19 (2005) 974-976
30. Spyridopoulos I., Haendeler J., Urbich C., Brummendorf T.H., Oh H., Schneider M.D., et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 110 (2004) 3136-3142
31. Urbich C., and Dimmeler S. Endothelial progenitor cells functional characterization. Trends Cardiovasc. Med. 14 (2004) 318-322
32. Ziche M., Morbidelli L., Parenti A., and Ledda F. Nitric oxide modulates angiogenesis elicited by prostaglandin E1 in rabbit cornea. Adv. Prostaglandin Thromboxane Leukot Res. 23 (1995) 495-497
33. Mehrabi M.R., Ekmekcioglu C., Stanek B., Thalhammer T., Tamaddon F., Pacher R., et al. Angiogenesis stimulation in explanted hearts from patients pre-treated with intravenous prostaglandin E(1). J. Heart Lung Transplant. 20 (2001) 465-473
34. Creutzig A., Lehmacher W., and Elze M. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV. Vasa 33 (2004) 137-144
35. Grant S.M., and Goa K.L. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 43 (1992) 889-924
36. Adams V., Lenk K., Linke A., Lenz D., Erbs S., Sandri M., et al. Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia. Arterioscler Thromb Vasc. Biol. 24 (2004) 684-690
37. Bonsignore M.R., Morici G., Santoro A., Pagano M., Cascio L., Bonanno A., et al. Circulating hematopoietic progenitor cells in runners. J. Appl. Physiol. 93 (2002) 1691-1697
38. Amendt K. PGE1 and other prostaglandins in the treatment of intermittent claudication: a meta-analysis. Angiology 56 (2005) 409-415